Biogen Rallies After Spinraza, Multiple Sclerosis Revenue Come In Light [Investor's Business Daily]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Investors Business Daily
Related news 4/23/2018 Merck popped to a three-month high Monday after Goldman Sachs suggested its cancer drug, Keytruda, could be a $16 billion... Ionis Shares Jump As It Deepens Biogen Ties In Neurology Drugs Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz Could This Tiny Biotech Rout Intercept In Liver Disease Drugs? How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal Exelixis Rebounds As Analyst Urges Investors To Buy Monday's Dip Bullish Session For Stock Market Early Ends Up Being Not So Bullish Biogen ( BIIB ) has a lofty view of its stock, an analyst said Tuesday after the No. 4 biotech reported first-quarter sales that lagged expectations on sluggish Spinraza and multiple sclerosis drug revenue. "The company came out and said its stock is 'very undervalued,' "
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.MarketBeat
- Wealth Of Korea's 50 Richest On Forbes List Rises To $115 Billion [Forbes]Forbes
- Merck (MRK) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Korea's 50 Richest 2024: AI Frenzy Boosts Combined Wealth To $115 Billion [Forbes]Forbes
- Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To [Seeking Alpha]Seeking Alpha
MRK
Earnings
- 2/1/24 - Beat
MRK
Sec Filings
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- MRK's page on the SEC website